TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03662334
Drug: Rapid Acting insulin with pre-treatment of rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylenex recombinant will be administered via infusion sets and insulin pumps. These will be compatible with component tubing system attached to the insulin infusion site and will be placed in the lower abdominal area.
Study: NCT00309777
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin once daily
Study: NCT01016483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00514449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic
Study: NCT02355379
Drug: LV5FU2 or capectitabine
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02355379
Drug: FOLFOX4 or XELOX
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02355379
Drug: LV5FU2 or capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01424566
Drug: Placebo (GA-0034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02226510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
Study: NCT02005601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
Study: NCT00724035
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 µg iv bolus prn for pain during surgery, up to 150 µg
Study: NCT04444700
Drug: Therapeutic anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of low molecular weight heparin (LMWH) versus unfractionated heparin (UFH) will be at the clinician's discretion. LMWH options include: Tinzaparin, Enoxaparin or Dalteparin. UFH will be administered using a weight-based nomogram with titration according to center-specific institutional protocol.
Study: NCT03151525
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AZA treatment after IFX withdrawal for maintenance of remission
Study: NCT04311476
Drug: 0.9% Sodiun Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Sodiun Chloride in control group
Study: NCT03388125
Drug: Injection Sclerotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% ethanolamine oleate group
Study: NCT02137772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
Study: NCT00581126
Drug: Recombinant Factor IX Coagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benefix IV each 12 hours for 2 a 5 days
Study: NCT01455571
Drug: HM781-36B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q1DX14/2W for 3W HM781-36B
Study: NCT00247390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
Study: NCT01949662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consisting of preservative free 0.9% normal saline given one time by vein.
Study: NCT01253460
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
Study: NCT01819220
Drug: hydrochlorothiazide/telmisartan
Normalized name: HYDROCHLOROTHIAZIDE/TELMISARTAN
Approvals — FDA: no, EMA: no, PMDA: no
Description: When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.~When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed.
Study: NCT00865462
Drug: Wellbutrin XL® 150 mg Tablet, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
Study: NCT00991172
Drug: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Subcutaneous injection
Study: NCT00048906
Drug: DRX005B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00627640
Drug: Safinimide 50-100 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safinamide, (S)-(+)-2-\[4-(3-fluorobenzyloxy) benzylamino\] propanamide methanesulfonate, is an a-aminoamide derivative
Study: NCT00627640
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03648996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of placebo treatment
Study: NCT01930734
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline solution 0.9% Placebo Arm
Study: NCT01856634
Drug: Optimized Background Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
Study: NCT01752517
Drug: NI group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
Study: NCT00317941
Drug: Betaferon/Betaseron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250ug administrated with Betaject
Study: NCT00317941
Drug: Betaferon/Betaseron
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250ug administrated with Betaject light
Study: NCT01259297
Drug: Placebo for Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for HCTZ 12.5/25 mg
Study: NCT02595060
Drug: inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: formulated as the active substance without molgramostim
Study: NCT00004865
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00592501
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
Study: NCT03894904
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 units/mL heparin administered as soon as the arterial catheter is placed and secured, and 2 units/mL heparin administered one hour after initial dose
Study: NCT02014532
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
Study: NCT00690937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01051388
Drug: Non-PPI (Gefarnate)
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
Study: NCT03174860
Drug: Diclofenac Potassium 50mg Tab
Normalized name: DICLOFENAC POTASSIUM 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
Study: NCT03174860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo will be taken one hour before initiation of endodontic treatment.
Study: NCT00436215
Drug: BAY 43-9006
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
Study: NCT01531218
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
Study: NCT01531218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04523285
Drug: TQB3728
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3728 tablets is a small molecule oral drug.
Study: NCT00001693
Drug: Celecoxib (SC-58635)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03536429
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT02644525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of placebo pill is given
Study: NCT02769572
Drug: placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 grams per knee, 4 times per day, for 4 weeks
Study: NCT02769572
Drug: diclofenac sodium gel
Normalized name: diclofenac sodium Topical Gel
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 grams per knee, 4 times per day, for 4 weeks
Study: NCT03230175
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
Study: NCT01459107
Drug: Bone marrow cell-based therapy & single-drug immunosuppression.
Approvals — FDA: no, EMA: no, PMDA: no
Description: This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
Study: NCT03344159
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.
Study: NCT03344159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for a total of duration of 12 weeks
Study: NCT00772512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, single dose
Study: NCT00962065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosing with daily oral intake for 28 days
Study: NCT03499041
Drug: LY3314814
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03042611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT00690716
Drug: Nasal CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
Study: NCT00690716
Drug: Inactive Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
Study: NCT03428191
Drug: Remifentanyl+Dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: In all patients, dexmedetomidine was injected at a bolus of 0.6 mg/kg and then continuously infused at 0.6 ug/kg/h using the conventional continuous microinfusion pump. the target Effect-site concentration of remifentanil was determined by sequential method.
Study: NCT00348972
Drug: Lantus® (insulin glargine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01539837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
Study: NCT00960440
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
Study: NCT00960440
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
Study: NCT00960440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
Study: NCT00960440
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
Study: NCT00960440
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
Study: NCT00960440
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
Study: NCT01099839
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00046319
Drug: BSF 208075
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02889510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-week subcutaneous placebo once daily
Study: NCT03799003
Drug: ASP1951
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously (IV)
Study: NCT01591746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A
Study: NCT02690480
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs
Study: NCT03177837
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT04125693
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any other drug specified in the protocol of the completed Bayer clinical trials that is used in combination with rogaratinib. Not all patients receive combination therapy.
Study: NCT02348216
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered according to package insert
Study: NCT02348216
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered according to package insert
Study: NCT00909987
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
Study: NCT00909987
Drug: Capecitabine during all Radiotherapy period
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 825 mg/m2 bid
Study: NCT02348216
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered according to package insert
Study: NCT00525317
Drug: Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg x 3 or placebo
Study: NCT00562159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sublingual tablet
Study: NCT04194216
Drug: Intra-operative single intravenous(iv) dose of cephalexin 2 g or clindamycin 900 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Arm A
Study: NCT04194216
Drug: Intra-operative single dose (iv) of cephalexin 2 g or clindamycin 900 mg and postoperative oral dose of cephalexin 250mg (every 4 hours) or clindamycin 150mg(every 6 hours) for 3 days
Normalized name: clindamycin Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Arm B
Study: NCT02606045
Drug: recombinant von Willebrand factor
Normalized name: VON WILLEBRAND FACTOR,RECOMBINANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.~Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4.
Study: NCT03585374
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each site will use the commercial available product already in use as per local clinical practice. The drug will be intravenously administered at a 100 mg dose. The time of infusion should be not longer than 10 minutes.
Study: NCT00637273
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, once a day
Study: NCT00637273
Drug: placebo once weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection, once a week
Study: NCT02616029
Drug: E/C/F/TAF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/10 mg FDC tablets administered orally once daily
Study: NCT00461266
Drug: Antiretroviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT01530399
Drug: MDCO 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
Study: NCT01530399
Drug: MDCO 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
Study: NCT01530399
Drug: MDCO 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
Study: NCT03716739
Drug: Testosterone Cypionate 100 MG/ML
Normalized name: testosterone cypionate 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg testosterone cypionate administered by intramuscular injection weekly for 12 weeks.
Study: NCT03716739
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by intramuscular injection weekly for 12 weeks.
Study: NCT02166593
Drug: Pravastatin40mg/Fenofibrate160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravafenix(Pravastatin40mg/Fenofibrate160mg)
Study: NCT00542685
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral, placebo BID, 8 weeks with 2 week taper.
Study: NCT03479879
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol
Study: NCT03479879
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00000539
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03994926
Drug: Cannabis cigarette - 4.0% THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: smoked cannabis 4.0% THC
Study: NCT02392546
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02533648
Drug: 2 capsules of lactose daily for 3 month
Normalized name: lactose Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules of lactose daily for 3 month
Study: NCT01897441
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01897441
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01897441
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ER-positive, HER2-negative disease may receive neoadjuvant endocrine therapy (NET) with an aromatase inhibitor: (either Anastrozole 1 mg po daily; Letrozole 2.5 mg po daily, Exemestane 25 mg po daily or Tamoxifen 20 mg po daily) for 4-6 months prior to surgery (or longer if clinically indicated). Anastrozole for 6 months is the preferred regimen for NET.
Study: NCT01308749
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray
Study: NCT03537924
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT01476046
Drug: GSK1995057 single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose
Study: NCT01476046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose
Study: NCT00320216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the placebo group will receive placebo medication.
Study: NCT03421197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: white tablet with no active ingredient manufactured to mimic Tepilamide Fumarate tablets
Study: NCT01705457
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00424697
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00424697
Drug: GW876008
Approvals — FDA: no, EMA: no, PMDA: no